The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Open accessAbstract
BACKGROUND: Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenström's macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect of adding ibrutinib to rituximab in patients with this disease, both in those who had not received previous treatment and in those with disease recurrence. METHODS: We randomly assigned 150 symptomatic patients to receive ibrutinib plus rituximab or placebo plus rituximab. The primary end point was progression-free survival, as assessed by an independent review committee. Key secondary end points were response rates, sustained hematologic improvement from baseline, and safety. The mutational status of MYD88 and CXCR4 was assessed in bone marrow samples. RESULTS: At 30 months, the progression-free survival rate was 82% with ibrutinib-rituximab versus 28% with placebo-rituximab (hazard ratio for progression or death, 0.20; P<0.001). The benefit in the ibrutinib-rituximab group over that in the placebo-rituximab group was independent of the MYD88 or CXCR4 genotype. The rate of major response was higher with ibrutinib-rituximab than with placebo-rituximab (72% vs. 32%, P<0.001). More patients had sustained increases in hemoglobin level with ibrutinib-rituximab than with placebo-rituximab (73% vs. 41%, P<0.001). The most common adverse events of any grade with ibrutinib-rituximab included infusion-related reactions, diarrhea, arthralgia, and nausea. Events of grade 3 or higher that occurred more frequently with ibrutinib-rituximab than with placebo-rituximab included atrial fibrillation (12% vs. 1%) and hypertension (13% vs. 4%); those that occurred less frequently included infusion reactions (1% vs. 16%) and any grade of IgM flare (8% vs. 47%). The major hemorrhage rate was the same in the two trial groups (4%). CONCLUSIONS: Among patients with Waldenström's macroglobulinemia, the use of ibrutinib-rituximab resulted in significantly higher rates of progression-free survival than the use of placebo-rituximab, both among those who had received no previous treatment and among those with disease recurrence. Atrial fibrillation and hypertension were more common with ibrutinib-rituximab, whereas infusion reactions and IgM flare were more common with placebo-rituximab. (Funded by Pharmacyclics and Janssen Research and Development; ClinicalTrials.gov number, NCT02165397 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Treon, S. P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R. J., Patterson, C. J., Tripsas, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200710 · Cited by 1,294
Self-citationIbrutinib in Previously Treated Waldenström’s Macroglobulinemia
Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., Argyropoulos, K. V., Yang, G., Cao, Y., Xu, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501548 · Cited by 942
Self-citationOwen, R. G., Treon, S. P., Al-Katib, A., Fonseca, R., Greipp, P. R., McMaster, M. L., Morra, E., Pangalis, G. A., San Miguel, J. F., Branagan, A. R., et al. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50082 · Cited by 924
Self-citationCella, D. F. (1997) · PubMed · Cited by 687
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., et al. (2015) · Blood · doi:10.1182/blood-2014-10-606038 · Cited by 663
International prognostic scoring system for Waldenström macroglobulinemia
Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M. A., Dhodapkar, M. V., McCoy, J., Crowley, J., Ocio, E. M., Garcia-Sanz, R., Treon, S. P., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174961 · Cited by 416
Self-citationWang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635326 · Cited by 410
How I treat Waldenström macroglobulinemia
Treon, S. P. (2015) · Blood · doi:10.1182/blood-2015-01-553974 · Cited by 287
Self-citationTreatment of Waldenström’s Macroglobulinemia With Rituximab
Dimopoulos, M. A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N. A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.039 · Cited by 253
Self-citationDimopoulos, M. A., Trotman, J., Tedeschi, A., Matous, J. V., Macdonald, D., Tam, C., Tournilhac, O., Ma, S., Oriol, A., Heffner, L. T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30632-5 · Cited by 240
Self-citationChang, B. Y., Huang, M. M., Francesco, M., Chen, J., Sokolove, J., Magadala, P., Robinson, W. H., & Buggy, J. J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3400 · Cited by 231
Dimopoulos, M. A., García-Sanz, R., Gavriatopoulou, M., Morel, P., Kyrtsonis, M.-C., Michalis, E., Kartasis, Z., Leleu, X., Palladini, G., Tedeschi, A., et al. (2013) · Blood · doi:10.1182/blood-2013-05-503862 · Cited by 208
Self-citationTreatment recommendations from the Eighth International Workshop on Waldenström’s Macroglobulinemia
Leblond, V., Kastritis, E., Advani, R., Ansell, S. M., Buske, C., Castillo, J. J., García-Sanz, R., Gertz, M., Kimby, E., Kyriakou, C., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711234 · Cited by 181
Self-citationDimopoulos, M. A., Kastritis, E., Owen, R. G., Kyle, R. A., Landgren, O., Morra, E., Leleu, X., García-Sanz, R., Munshi, N., Anderson, K. C., et al. (2014) · Blood · doi:10.1182/blood-2014-03-565135 · Cited by 169
Self-citationRuella, M., Kenderian, S. S., Shestova, O. E., Klichinsky, M., Melenhorst, J. J., Wasik, M. A., Lacey, S. F., June, C. H., & Gill, S. I. (2016) · Leukemia · doi:10.1038/leu.2016.262 · Cited by 133
Guidelines on the diagnosis and management of W aldenström macroglobulinaemia
Owen, R. G., Pratt, G., Auer, R. L., Flatley, R., Kyriakou, C. A., Lunn, M. P., Matthey, F., McCarthy, H. O., McNicholl, F. P., Rassam, S. M. B., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12760 · Cited by 52
Zhang, L., Zhang, H., Zhao, D., Tsourdinis, G. E., Park, H., Tamayo, A. T., Pham, L. V., Ford, R. J., Fang, B., & Wang, M. L. (2014) · Blood · doi:10.1182/blood.v124.21.1774.1774 · Cited by 4
Cited by
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Moreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., Simkovic, M., Samoilova, O., Novak, J., Ben-Yehuda, D., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30788-5 · Cited by 556
Self-citationTam, C. S., Opat, S., D'Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Marlton, P., Wahlin, B. E., Sanz, R. G., et al. (2020) · Blood · doi:10.1182/blood.2020006844 · Cited by 466
Self-citationThe regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
Pavlasova, G., & Mraz, M. (2020) · Haematologica · doi:10.3324/haematol.2019.243543 · Cited by 433
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Wen, T., Wang, J., Shi, Y., Qian, H., & Liu, P. (2021) · Leukemia · doi:10.1038/s41375-020-01072-6 · Cited by 262
Metadata
- Authors
- Dimopoulos, M. A., Tedeschi, A., Trotman, J., García-Sanz, R., Macdonald, D., Leblond, V., Mahe, B., Herbaux, C., Tam, C., Orsucci, L., Palomba, M. L., Matous, J. V., Shustik, C., Kastritis, E., Treon, S. P., Li, J., Salman, Z., Graef, T., & Buske, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-06-21
- Volume
- 378
- Issue
- 25
- Pages
- 2399-2410
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2805689516
- Cited by
- 357
- References
- 18
- FWCI
- 23.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.